Your GLP-1 coverage changed. Here’s what to do next.
As of October 16, 2026, if your insurance stopped covering Wegovy, Zepbound or another GLP-1 medication, check your options in this order: ask your prescriber about resubmitting the prior authorization or appealing, compare the manufacturers’ self-pay prices, see whether you qualify for Medicare’s GLP-1 Bridge ($50 copayment for a one-month supply), and then consider other routes, including compounded medication prescribed by a licensed provider. Compounded medications are not FDA-approved. They are prepared by state-licensed pharmacies based on a valid prescription from a licensed provider. Compounded medications are not therapeutically equivalent to FDA-approved products. Before you change or stop anything, talk to your prescriber; the right next step depends on your history.
Last verified: October 16, 2026. Prices and program terms change; confirm with the source before you decide.
My insurance is ending weight-loss GLP-1 coverage. What should I do?
As of October 16, 2026, if your employer or insurer is dropping coverage of GLP-1 medications for weight loss, usually at your plan’s renewal date (January 1 for many plans), start with the notice itself: note the exact end date and whether the plan will still cover GLP-1s for other conditions, such as type 2 diabetes. Then ask your prescriber whether your medical history meets any criteria the plan will continue to cover. If you can choose between plans at open enrollment, including a spouse’s plan, check each plan’s 2027 formulary before you pick one. If your coverage does end, compare the manufacturers’ self-pay prices listed below, check whether you qualify for Medicare’s GLP-1 Bridge, and then consider other routes, including compounded medication prescribed by a licensed provider. Compounded medications are not FDA-approved. They are prepared by state-licensed pharmacies based on a valid prescription from a licensed provider. Compounded medications are not therapeutically equivalent to FDA-approved products.
What changed in 2026, what’s coming in 2027, and the dates to know
My prior authorization or renewal was denied. What now?
As of October 16, 2026, a denied prior authorization is not always final (HealthCare.gov, checked September 24, 2026). Start with the denial letter, which should state the reason and explain how to appeal. Renewals are often denied because your BMI is now below the plan’s starting criteria, because the plan adopted new criteria for the plan year, or because it requires you to try a different drug first. Ask your prescriber whether a resubmission can document your weight history before treatment and any related health conditions, and whether a formulary alternative is covered. If the resubmission fails, most plans must offer an internal appeal and then an external review by an independent third party (HealthCare.gov); Medicare and some older plans follow different rules. If the appeal does not succeed, compare manufacturer self-pay prices, check Medicare Bridge eligibility if you have Part D, and consider other routes, including compounded medication prescribed by a licensed provider. Compounded medications are not FDA-approved. They are prepared by state-licensed pharmacies based on a valid prescription from a licensed provider. Compounded medications are not therapeutically equivalent to FDA-approved products.
I lost my job, or my COBRA coverage is ending. What are my options?
As of October 16, 2026, losing job-based insurance usually ends your GLP-1 coverage with it, unless you keep the same plan through COBRA, which generally means paying the full premium for a limited time. Note the exact date your coverage ends, and check the formulary of every plan you could move to, such as a spouse’s employer plan or a Marketplace plan. HealthCare.gov open enrollment for 2027 coverage runs November 1, 2026 to January 15, 2027, and December 15 is the last day to enroll for coverage that starts January 1 (per HealthCare.gov, checked September 24, 2026; state-run marketplaces can differ). Losing job-based coverage can also qualify you for a Special Enrollment Period outside those dates. If no plan covers your medication, compare manufacturer self-pay prices and check Medicare Bridge eligibility if you have Part D. You can also ask a licensed provider whether a different treatment, including compounded medication, is appropriate for you. Compounded medications are not FDA-approved. They are prepared by state-licensed pharmacies based on a valid prescription from a licensed provider. Compounded medications are not therapeutically equivalent to FDA-approved products.
I’m turning 65 or moving to Medicare. Will my GLP-1 still be covered?
As of October 16, 2026, CMS describes the Medicare GLP-1 Bridge as a short-term demonstration running July 1, 2026 through December 31, 2027, outside the regular Part D benefit and payment flow. Humana processes claims for CMS. For weight management with lifestyle modification, it covers all formulations of Foundayo™, Wegovy® injection (including Wegovy HD) and tablets, and Zepbound® KwikPen® only. Zepbound single-dose vials and single-dose pens are not covered. The Bridge does not cover compounded drugs. As of October 16, 2026, CMS excludes people with type 2 diabetes, moderate-to-severe obstructive sleep apnea, or noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH); ask your Part D plan about coverage for those conditions. Anyone who received a GLP-1 through Part D in calendar 2026 is ineligible for the Bridge in 2026. CMS has not yet set the relevant lookback period for 2027. Ask your prescriber and pharmacy about the criteria, $50 copayment for a one-month supply and pharmacy-initiated prior authorization below.
I’m switching telehealth providers. How do I avoid a gap?
As of October 16, 2026, before you cancel your current provider, gather your records: the medication name, your current dose, the date of your last dose, and a photo of the pharmacy label or your prescription. Check your current provider’s cancellation terms and next renewal date so you are not billed for a shipment you no longer want; the GLP-1 Telehealth Cancellation & Refund Policy Index lists the published terms of 18 providers. Share your full history with the new provider. Brand-name and compounded doses are not interchangeable, and there is no dose conversion between them; your provider determines the right dose based on your history. Tell the provider how long it has been since your last dose. Compounded medications are not FDA-approved. They are prepared by state-licensed pharmacies based on a valid prescription from a licensed provider. Compounded medications are not therapeutically equivalent to FDA-approved products. If your reason for switching is price, compare the manufacturer self-pay prices below too.
Switching? What to have ready, and how to avoid a gap in treatment
I’m restarting after a break. What dose do I start at?
As of October 16, 2026, your provider determines the right restart dose based on your history, including how long you have been off, the dose you were on, and how you tolerated it. Do not restart at your previous dose on your own. Before your appointment, write down the medication and dose you last took, the date of your last dose, and why you stopped. If the break was caused by coverage, ask your prescriber whether a prior authorization needs to be resubmitted. If you pay out of pocket, compare the manufacturer self-pay prices below. At LillyDirect, if more than 45 days pass after your previous delivery, Zepbound 7.5 mg to 15 mg moves from $449 to the regular price of $499 (7.5 mg) or $699 (10 mg to 15 mg). Compounded medication prescribed by a licensed provider is another option. Compounded medications are not FDA-approved. They are prepared by state-licensed pharmacies based on a valid prescription from a licensed provider. Compounded medications are not therapeutically equivalent to FDA-approved products.
My GLP-1 price went up. Why, and what can I do?
As of October 16, 2026, find out which of three things changed. First, your insurance: a new plan year can move a drug to a higher tier or add a deductible, so ask your plan what you will pay in 2027. Second, a manufacturer offer: Lilly’s Zepbound Savings Card and its KwikPen self-pay program both end December 31, 2026 (Savings Card terms checked September 24, 2026; KwikPen terms checked October 16, 2026), NovoCare’s $199 Wegovy price covers only a new patient’s first two monthly fills, and NovoCare says its pricing will be updated after December 31, 2026. Third, refill timing: LillyDirect’s $449 price for Zepbound 7.5 mg to 15 mg applies on the first fill and on refills within 45 days of your previous delivery; after that, regular prices of $499 to $699 apply. If a telehealth provider raised your price, compare the total monthly cost, including any membership fee. Compounded medication prescribed by a licensed provider is one option to compare. Compounded medications are not FDA-approved. They are prepared by state-licensed pharmacies based on a valid prescription from a licensed provider. Compounded medications are not therapeutically equivalent to FDA-approved products.
Which options should you check first?
These are the routes to check, in the order most people should check them. Each one stands on its own; skip any that do not apply to you.
1. Can your prescriber resubmit or appeal?
As of October 16, 2026, your first call is to the prescriber who submitted the original prior authorization. Ask for the plan’s written coverage criteria and the exact reason for any denial, then ask whether a resubmission can include your weight history before treatment and any related health conditions. If the plan denies it again, most plans must offer an internal appeal and then an external review by an independent third party, according to HealthCare.gov (checked September 24, 2026). Medicare and some older grandfathered plans follow different rules; your denial letter and plan documents explain the steps and deadlines for your plan.
2. What are the manufacturers’ self-pay prices?
Eli Lilly (LillyDirect) and Novo Nordisk (NovoCare Pharmacy) offer self-pay programs for Zepbound, Wegovy and Foundayo to patients with a valid prescription. These are the published prices, per Lilly’s LillyDirect and Zepbound savings pages and Novo Nordisk’s NovoCare pages, checked October 16, 2026:
| Medication | Seller | Self-pay price per month |
|---|---|---|
| Zepbound vial, 2.5 mg | LillyDirect | $299 |
| Zepbound vial, 5 mg | LillyDirect | $399 |
| Zepbound vial, 7.5, 10, 12.5 or 15 mg | LillyDirect | $449 on the first fill and on refills within 45 days of your previous delivery; otherwise $499 (7.5 mg) or $699 (10, 12.5 or 15 mg) |
| Zepbound KwikPen, 2.5 mg, 5 mg, or 7.5 to 15 mg | LillyDirect | $299, $399 or $449 (same 45-day rule) through Lilly’s KwikPen self-pay program, which ends December 31, 2026 and allows up to 11 fills a year |
| Wegovy pen 0.25 mg or 0.5 mg, new patients | NovoCare Pharmacy | $199 for the first two monthly fills, through December 31, 2026 |
| Wegovy pen 0.25 mg to 2.4 mg | NovoCare Pharmacy | $349 |
| Wegovy HD 7.2 mg | NovoCare Pharmacy | $399 |
| Foundayo™ tablets (LillyDirect terms verified October 16, 2026) | LillyDirect | $149 (0.8 mg); temporary $149 (2.5 mg) / $199 (5.5 mg) through December 31, 2026, otherwise $199 / $299; $299 (9 mg); $299 (14.5 or 17.2 mg) with refill within 45 days, otherwise $349; card ends December 31, 2026; 30-day supply; valid prescription and program terms apply |
| Wegovy pill | NovoCare Pharmacy | $149 (1.5 mg), $199 (4 mg), $299 (9 mg or 25 mg) per bottle of 30 tablets; valid prescription and NovoCare eligibility terms; pricing to be updated after December 31, 2026 |
- Manufacturer programs apply to FDA-approved brands, not compounded drugs. Compounded medications are not FDA-approved. They are prepared by state-licensed pharmacies based on a valid prescription from a licensed provider. Compounded medications are not therapeutically equivalent to FDA-approved products.
- As of October 16, 2026, LillyDirect lists a 30-day Foundayo™ supply at regular prices of $149 (0.8 mg), $199 (2.5 mg), $299 (5.5 mg or 9 mg), and $349 (14.5 mg or 17.2 mg). Through December 31, 2026, the 2.5 mg price is temporarily $149 and the 5.5 mg price is $199. The 14.5 mg and 17.2 mg doses are $299 per month when refilled within 45 days; otherwise $349. The self-pay card expires and savings end December 31, 2026. A valid prescription and program terms apply (LillyDirect terms modified September 15, 2026).
- As of October 16, 2026, TrumpRx.gov lists manufacturer offers and routes patients to LillyDirect or Novo pharmacy coupons. You cannot buy drugs directly from TrumpRx. It is not insurance, does not cover compounded drugs, and cash/TrumpRx purchases do not count toward a Medicare deductible or out-of-pocket maximum. Confirm the product, dose, refill deadline and eligibility with the manufacturer; no separate TrumpRx price is quoted here.
- Novo Nordisk’s February 24, 2026 announcement sets the list price (wholesale acquisition cost) of Wegovy® 2.4 mg injection and 25 mg tablets at $675 effective January 1, 2027. As verified October 16, 2026, Novo says self-pay prices are not affected. List price is not a patient self-pay quote; 2027 self-pay prices have not been published.
- LillyDirect defines a month as 28 days: four single-dose vials or one KwikPen. Injection supplies are sold separately: pen needles for the KwikPen, and needles and syringes for vials.
- Among Lilly’s Zepbound offers, the vial self-pay prices show no end date. Lilly’s KwikPen self-pay program and its Zepbound Savings Card for people with commercial insurance both end December 31, 2026 (Savings Card terms checked September 24, 2026; KwikPen terms checked October 16, 2026).
- NovoCare states that its pricing will be updated after December 31, 2026. Novo Nordisk says government-insured patients may use its Wegovy self-pay pricing if they pay outside their insurance.
3. Do you qualify for Medicare’s GLP-1 Bridge?
As of October 16, 2026, CMS describes the Medicare GLP-1 Bridge as a short-term demonstration running July 1, 2026 through December 31, 2027, outside the regular Part D benefit and payment flow. Humana processes claims for CMS. For weight management with lifestyle modification, it covers all formulations of Foundayo™, Wegovy® injection (including Wegovy HD) and tablets, and Zepbound® KwikPen® only. Zepbound single-dose vials and single-dose pens are not covered. The Bridge does not cover compounded drugs.
As of October 16, 2026, Medicare.gov lists a $50 copayment for a one-month supply (28 or 30 days, depending on the drug), at any income. No Part D deductible applies, and the payment does not count toward the Part D out-of-pocket cap. Extra Help/low-income subsidies and the Medicare Prescription Payment Plan do not apply. Coupons and discount programs cannot be applied to Bridge claims. Pen needles are not covered.
As of October 16, 2026, CMS requires enrollment in an eligible Part D plan: a standalone prescription drug plan (PDP), or a Medicare Advantage drug plan that is an HMO, HMOPOS, or local or regional PPO; Special Needs Plans (SNPs), employer group waiver plans (EGWPs) and LI NET are eligible. Private fee-for-service plans, section 1876 cost-contract plans, section 1833 health care prepayment plans, PACE, fallback plans and religious fraternal benefit plans are excluded unless the person also has a standalone PDP.
As of October 16, 2026, CMS requires age 18 or older and one of these criteria when GLP-1 therapy was initiated, including therapy started before Part D enrollment or July 1, 2026: BMI at least 35; BMI at least 30 with heart failure with preserved ejection fraction, uncontrolled hypertension, or chronic kidney disease stage 3a or above; or BMI at least 27 with prediabetes, a previous heart attack, a previous stroke, or symptomatic peripheral artery disease. The prescription must be for weight management with lifestyle modification.
As of October 16, 2026, CMS excludes people with type 2 diabetes, moderate-to-severe obstructive sleep apnea, or noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH); ask your Part D plan about coverage for those conditions. Anyone who received a GLP-1 through Part D in calendar 2026 is ineligible for the Bridge in 2026. CMS has not yet set the relevant lookback period for 2027.
As of October 16, 2026, the process starts with the prescriber sending a prescription to the pharmacy. The pharmacy claim establishes program eligibility; the pharmacy then requests prior authorization from the prescriber (allow 24–72 hours). The prescriber should wait for that request before submitting the authorization. A decision follows within 72 hours and a letter is mailed. Approval covers refills and dose changes through December 31, 2027 unless the GLP-1 drug changes. There is no Bridge appeals process; resubmission is allowed.
As of October 16, 2026, CMS identifies $245 per monthly supply as the manufacturer net price to the Bridge, not the patient copayment. The separate IRA Medicare Drug Price Negotiation fact sheet lists a $274 negotiated 30-day price for semaglutide products (Ozempic®/Rybelsus®/Wegovy®), effective January 1, 2027. That is a different program and is not a patient quote or a promise of Part D coverage for weight loss.
4. Is compounded medication appropriate for you?
As of October 16, 2026, some people ask a licensed provider whether compounded semaglutide or compounded tirzepatide is appropriate for them. Compounded medications are not FDA-approved. They are prepared by state-licensed pharmacies based on a valid prescription from a licensed provider. Compounded medications are not therapeutically equivalent to FDA-approved products. A licensed provider decides whether compounded medication is appropriate for you. Brand-name and compounded doses are not interchangeable, and there is no dose conversion between them; your provider determines the right dose based on your history. If you consider this route, ask who prescribes, which pharmacy prepares the medication, and exactly what the monthly price includes.
Where does Cora Health fit?
As of October 16, 2026, Cora Health is one cash-pay option; check a coverage appeal, manufacturer self-pay and Medicare Bridge eligibility first. Cora Health connects patients with licensed providers at Wasef Health, PC, who may prescribe compounded semaglutide or compounded tirzepatide injections when appropriate. Medication is prepared by US-licensed 503A compounding pharmacies, including Hallandale Pharmacy (PCAB-accredited) and VialsRx. Cora Health does not prescribe or compound medication. Compounded medications are not FDA-approved. They are prepared by state-licensed pharmacies based on a valid prescription from a licensed provider. Compounded medications are not therapeutically equivalent to FDA-approved products.
As of October 16, 2026, the Essential Plan for compounded semaglutide injections prescribed through Cora Health is $99/month ($1,188 billed upfront every 12 months); $120/month ($720 billed upfront every 6 months); $145/month ($435 billed upfront every 3 months); $175/month ($175 billed monthly). Plans renew automatically until you cancel. Prices may change. Includes licensed-provider consultation, medication, pharmacy fulfillment, expedited shipping and ongoing monitoring. A licensed provider decides eligibility. Cancellation and refund policy. Compounded medications are not FDA-approved. They are prepared by state-licensed pharmacies based on a valid prescription from a licensed provider. Compounded medications are not therapeutically equivalent to FDA-approved products.
As of October 16, 2026, the Premium Plan for compounded tirzepatide injections prescribed through Cora Health is $135/month ($1,620 billed upfront every 12 months); $175/month ($1,050 billed upfront every 6 months); $199/month ($597 billed upfront every 3 months); $225/month ($225 billed monthly). Plans renew automatically until you cancel. Prices may change. Includes licensed-provider consultation, medication, pharmacy fulfillment, expedited shipping and ongoing monitoring. A licensed provider decides eligibility. Cancellation and refund policy. Compounded medications are not FDA-approved. They are prepared by state-licensed pharmacies based on a valid prescription from a licensed provider. Compounded medications are not therapeutically equivalent to FDA-approved products.
Compounded semaglutide and compounded tirzepatide are not FDA-approved. They are prepared by state-licensed pharmacies based on a valid prescription from a licensed provider. Compounded medications are not therapeutically equivalent to FDA-approved products. Cora Health does not prescribe or compound medication; licensed providers make all prescribing decisions. This page is general information, not medical, legal or insurance advice. Wegovy®, Zepbound®, Ozempic® and Rybelsus® are registered trademarks of their respective owners; NovoCare, LillyDirect, KwikPen and Foundayo™ are trademarks of their respective owners. Cora Health is not affiliated with Novo Nordisk or Eli Lilly.
Where do these facts come from?
Manufacturer prices and Medicare Bridge rules were re-verified using the sources below. Enrollment and appeal sources retain their September 24, 2026 checks. Last price/program verification: October 16, 2026.
- CMS — Bridge information for Part D plans (August 6, 2026; verified October 16, 2026)
- CMS — Bridge information for providers (August 6, 2026; verified October 16, 2026)
- Medicare.gov — weight-loss drugs (verified October 16, 2026)
- Medicare — GLP-1 Bridge fact sheet 12234 (June 2026; verified October 16, 2026)
- CMS — separate IRA negotiated prices effective January 1, 2027
- LillyDirect — Foundayo self-pay terms (September 15, 2026; verified October 16, 2026)
- LillyDirect — Foundayo (September 2026; verified October 16, 2026)
- NovoCare — Wegovy tablet pricing (verified October 16, 2026)
- NovoCare — Wegovy eligibility and terms (verified October 16, 2026)
- NovoCare — Wegovy savings offer (verified October 16, 2026)
- TrumpRx — manufacturer listings (verified October 16, 2026)
- Novo Nordisk — January 2027 list-price announcement (February 24, 2026; verified October 16, 2026)
- Eli Lilly — LillyDirect Zepbound self-pay pricing (checked October 16, 2026)
- Eli Lilly — KwikPen self-pay program terms (checked October 16, 2026); Zepbound Savings Card terms (checked September 24, 2026)
- Novo Nordisk — NovoCare Pharmacy Wegovy pricing (checked October 16, 2026)
- CMS — Medicare GLP-1 Bridge (checked October 16, 2026)
- Medicare.gov — Joining a plan: Open Enrollment dates (checked September 24, 2026)
- HealthCare.gov — Dates and deadlines for 2027 coverage (checked September 24, 2026)
- HealthCare.gov — Appealing a health insurance company decision (checked September 24, 2026)
Coverage changes FAQ
Compare every option before you decide
If compounded medication is one of the options you are weighing, a licensed provider decides whether it is right for you. Compounded medications are not FDA-approved. They are prepared by state-licensed pharmacies based on a valid prescription from a licensed provider. Compounded medications are not therapeutically equivalent to FDA-approved products.